{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:26:18Z","timestamp":1791973578737,"version":"4.4.0"},"reference-count":91,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Cystic Fibrosis Foundation","award":["FFC#5\/2022"],"award-info":[{"award-number":["FFC#5\/2022"]}]},{"name":"Italian Cystic Fibrosis Foundation","award":["FFC#18\/2021"],"award-info":[{"award-number":["FFC#18\/2021"]}]},{"name":"Italian Cystic Fibrosis Foundation","award":["FFC#5\/2022"],"award-info":[{"award-number":["FFC#5\/2022"]}]},{"name":"Italian Cystic Fibrosis Foundation","award":["FFC#18\/2021"],"award-info":[{"award-number":["FFC#18\/2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mycobacterium abscessus is an opportunistic pathogen that mainly colonizes and infects cystic fibrosis patients\u2019 lungs. M. abscessus is naturally resistant to many antibiotics such as rifamycin, tetracyclines and \u03b2-lactams. The current therapeutic regimens are not very effective and are mostly based on repurposed drugs used against Mycobacterium tuberculosis infections. Thus, new approaches and novel strategies are urgently needed. This review aims to provide an overview of the latest ongoing findings to fight M. abscessus infections by analyzing emerging and alternative treatments, novel drug delivery strategies, and innovative molecules.<\/jats:p>","DOI":"10.3390\/ijms24054635","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T03:00:38Z","timestamp":1677553238000},"page":"4635","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options"],"prefix":"10.3390","volume":"24","author":[{"given":"Deborah","family":"Recchia","sequence":"first","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-4770","authenticated-orcid":false,"given":"Giovanni","family":"Stelitano","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-1501","authenticated-orcid":false,"given":"Alessandro","family":"Stamilla","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2867-3664","authenticated-orcid":false,"given":"Damaris L.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-8311","authenticated-orcid":false,"given":"Giulia","family":"Degiacomi","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-9764","authenticated-orcid":false,"given":"Laurent R.","family":"Chiarelli","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-4937","authenticated-orcid":false,"given":"Maria Rosalia","family":"Pasca","sequence":"additional","affiliation":[{"name":"Department of Biology and Biotechnology \u201cL. Spallanzani\u201d, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.11-2348","article-title":"Defective phagocytosis in airways disease","volume":"141","author":"Donnelly","year":"2012","journal-title":"Chest"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ncb1456","article-title":"CFTR regulates phagosome acidification in macrophages and alters bactericidal activity","volume":"8","author":"Di","year":"2006","journal-title":"Nat. Cell. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3389\/fmicb.2018.02642","article-title":"Mycobacterium abscessus: Shapeshifter of the Mycobacterial World","volume":"9","author":"Ryan","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: A clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1542\/peds.23.3.545","article-title":"A Test for Concentration of Electrolytes in Sweat in Cystic Fibrosis of the Pancreas Utilizing Pilocarpine by Iontophoresis","volume":"23","author":"Gibson","year":"1959","journal-title":"Pediatrics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_8","unstructured":"Dorfman, R., and For the CFMD\/CFTR1 Team (2022, November 22). Cystic Fibrosis Mutation Database. Available online: http:\/\/www.genet.sickkids.on.ca\/cftr\/app."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"Freedman","year":"2009","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ppul.24366","article-title":"Gene modifiers of cystic fibrosis lung disease: A systematic review","volume":"54","author":"Shanthikumar","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dagenais, R.V.E., Su, V.C.H., and Quon, B.S. (2020). Real-world safety of CFTR modulators in the treatment of cystic fibrosis: A systematic review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010023"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-2004-829501","article-title":"Mycobacterial infections caused by nontuberculous mycobacteria","volume":"25","author":"Heifets","year":"2004","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dubois, V., Pawlik, A., Bories, A., Le Moigne, V., Sismeiro, O., Legendre, R., Varet, H., Rodriguez-Ordonez, M.D.P., Gaillard, J.L., and Coppee, J.Y. (2019). Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages. PLoS Pathog., 15.","DOI":"10.1101\/529057"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.thorsurg.2018.09.008","article-title":"Nontuberculous mycobacterial infections in cystic fibrosis","volume":"29","author":"Martiniano","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pulmoe.2017.12.005","article-title":"Non-tuberculous mycobacterial pulmonary infections","volume":"24","author":"Chalmers","year":"2018","journal-title":"Pulmonology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1099\/ijsem.0.001376","article-title":"Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov","volume":"66","author":"Tortoli","year":"2016","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Abdelaal, H.F.M., Chan, E.D., Young, L., Baldwin, S.L., and Coler, R.N. (2022). Mycobacterium abscessus: It\u2019s Complex. Microorganisms, 10.","DOI":"10.3390\/microorganisms10071454"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1017\/S0950268816002521","article-title":"Non-tuberculous mycobacteria: Epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease","volume":"145","author":"Mencarini","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, & Infectious Disease Society of America. An official ATS\/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Amer. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3389\/fmicb.2018.02179","article-title":"The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance","volume":"9","author":"Luthra","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01206-17","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","article-title":"Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/ijmy.ijmy_181_19","article-title":"Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus","volume":"9","author":"Martin","year":"2020","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e00705-19","DOI":"10.1128\/AAC.00705-19","article-title":"Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages","volume":"63","author":"Viljoen","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1700083","DOI":"10.1183\/13993003.00083-2017","article-title":"Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections","volume":"49","author":"Vesenbeckh","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bento, C.M., Gomes, M.S., and Silva, T. (2020). Looking beyond typical treatments for atypical mycobacteria. Antibiotics, 9.","DOI":"10.3390\/antibiotics9010018"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Meir, M., and Barkan, D. (2020). Alternative and experimental therapies of Mycobacterium abscessus infections. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202008.0273.v1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14656566.2020.1740205","article-title":"State-of-the-art treatment strategies for nontuberculous mycobacteria infections","volume":"21","author":"Esteban","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.micinf.2015.01.004","article-title":"How bacterial pathogens colonize their hosts and invade deeper tissues","volume":"17","author":"Ribet","year":"2015","journal-title":"Microbes. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1356540","DOI":"10.1155\/2019\/1356540","article-title":"Intracellular pathogens: Host immunity and microbial persistence strategies","volume":"2019","author":"Thakur","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2017.23","article-title":"Different drugs for bad bugs: Antivirulence strategies in the age of antibiotic resistance","volume":"16","author":"Dickey","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Degiacomi, G., Sammartino, J.C., Chiarelli, L.R., Riabova, O., Makarov, V., and Pasca, M.R. (2019). Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235868"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijmy.ijmy_167_18","article-title":"Antimicrobial properties of basidiomycota macrofungi to Mycobacterium abscessus isolated from patients with cystic fibrosis","volume":"8","author":"Millar","year":"2019","journal-title":"Int. J. Mycobacteriol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"acmi000154","DOI":"10.1099\/acmi.0.000154","article-title":"Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease","volume":"2","author":"Bogdanovski","year":"2020","journal-title":"Access. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nrmicro1004","article-title":"Antimicrobial reactive oxygen and nitrogen species: Concepts and controversies","volume":"2","author":"Fang","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: Regulation and function","volume":"33","author":"Forstermann","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bernut, A., Nguyen-Chi, M., Halloum, I., Herrmann, J.L., Lutfalla, G., and Kremer, L. (2016). Mycobacterium abscessus-induced granuloma formation is strictly dependent on tnf signaling and neutrophil trafficking. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005986"},{"key":"ref_46","first-page":"283","article-title":"Upregulation of inducible nitric oxide synthase and cytokine secretion in peripheral blood monocytes from pulmonary tuberculosis patients","volume":"5","author":"Wang","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"Bentur","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1183\/09031936.99.13111499","article-title":"Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome","volume":"13","author":"Grasemann","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1183\/09031936.04.00086104","article-title":"Oral L-arginine supplementation in cystic fibrosis patients: A placebo-controlled study","volume":"25","author":"Grasemann","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.200509-1439OC","article-title":"Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis","volume":"174","author":"Grasemann","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.niox.2008.08.002","article-title":"Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure","volume":"20","author":"Miller","year":"2009","journal-title":"Nitric Oxide"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jcf.2012.01.003","article-title":"A phase I clinical study of inhaled nitric oxide in healthy adults","volume":"11","author":"Miller","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s15010-016-0879-x","article-title":"Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: A phase I clinical study","volume":"44","author":"Deppisch","year":"2016","journal-title":"Infection"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate Nitric Oxide adjuvant treatment of persistent Mycobacterium infection in cystic fibrosis patients","volume":"37","author":"Gur","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1073\/pnas.93.8.3167","article-title":"Smaller fleas... ad infinitum: Therapeutic bacteriophage redux","volume":"93","author":"Lederberg","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1155\/2007\/976850","article-title":"Phage as an antimicrobial agent: d\u2019Herelle\u2019s heretical theories and their role in the decline of phage prophylaxis in the West","volume":"18","author":"Fruciano","year":"2007","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Romero-Calle, D., Guimaraes Benevides, R., Goes-Neto, A., and Billington, C. (2019). Bacteriophages as alternatives to antibiotics in clinical care. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030138"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","article-title":"A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy","volume":"34","author":"Wright","year":"2009","journal-title":"Clin. Otolaryngol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13054-017-1709-y","article-title":"Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report","volume":"21","author":"Jennes","year":"2017","journal-title":"Crit. Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.tibtech.2010.08.001","article-title":"Bacteriophages as potential new therapeutics to replace or supplement antibiotics","volume":"28","author":"Kutateladze","year":"2010","journal-title":"Trends Biotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: Compassionate-use of phages in twenty patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","first-page":"1795","article-title":"The arsenal of pathogens and antivirulence therapeutic strategies for disarming them","volume":"10","author":"Brannon","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/fmb-2019-0294","article-title":"Antivirulence compounds: A future direction to overcome antibiotic resistance?","volume":"15","author":"Buroni","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"938895","DOI":"10.3389\/fimmu.2022.938895","article-title":"Virulence-associated secretion in Mycobacterium abscessus","volume":"13","author":"Meir","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/17460913.3.4.415","article-title":"Living on the edge: Inhibition of host cell apoptosis by Mycobacterium tuberculosis","volume":"3","author":"Briken","year":"2008","journal-title":"Future Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/s41564-022-01204-x","article-title":"Mycobacterium abscessus pathogenesis identified by phenogenomic analyses","volume":"7","author":"Boeck","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrmicro1098","article-title":"Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria?","volume":"3","author":"Brogden","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1021\/cb800240j","article-title":"Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs","volume":"4","author":"Cherkasov","year":"2009","journal-title":"ACS Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"151855","DOI":"10.1016\/j.scitotenv.2021.151855","article-title":"Antibacterial peptide RP557 increases the antibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilm formation","volume":"807","author":"Li","year":"2022","journal-title":"Sci. Total Environ."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.resmic.2020.03.001","article-title":"Antimicrobial peptides against drug resistant Mycobacterium abscessus","volume":"171","author":"Gupta","year":"2020","journal-title":"Res. Microbiol."},{"key":"ref_75","first-page":"273","article-title":"Non-disulfide-Bridge Peptide 5.5 from the Scorpion Hadrurus gertschi Inhibits the Growth of Mycobacterium abscessus subsp","volume":"8","author":"Trentini","year":"2017","journal-title":"massiliense. Front. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"das Neves, R.C., Trentini, M.M., de Castro e Silva, J., Simon, K.S., Bocca, A.L., Silva, L.P., Mortari, M.R., Kipnis, A., and Junqueira-Kipnis, A.P. (2016). Antimycobacterial activity of a new peptide polydim-i isolated from neotropical social wasp Polybia dimorpha. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149729"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijantimicag.2016.11.013","article-title":"Evaluation of the antimicrobial activity of the mastoparan Polybia-MPII isolated from venom of the social wasp Pseudopolybia vespiceps testacea (Vespidae, Hymenoptera)","volume":"49","author":"Silva","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\u00ae\/CAELYX\u00ae) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejpb.2018.02.022","article-title":"Recent advances on antimicrobial wound dressing: A review","volume":"127","author":"Simoes","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/acs.jmedchem.0c00373","article-title":"Shedding X-ray light on the role of magnesium in the activity of Mycobacterium tuberculosis salicylate synthase (MbtI) for drug design","volume":"63","author":"Mori","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1128\/JB.181.15.4443-4451.1999","article-title":"Iron acquisition and metabolism by mycobacteria","volume":"181","author":"Rutter","year":"1999","journal-title":"J. Bacteriol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1021\/acs.molpharmaceut.7b01036","article-title":"In vitro efficacy of free and nanoparticle formulations of gallium(III) meso-tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and gallium biodistribution in mice","volume":"15","author":"Choi","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijerph7052337","article-title":"Medical applications and toxicities of gallium compounds","volume":"7","author":"Chitambar","year":"2010","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.nano.2019.102125","article-title":"PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus","volume":"24","author":"Goes","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Rinaldi, F., Hanieh, P.N., Sennato, S., De Santis, F., Forte, J., Fraziano, M., Casciardi, S., Marianecci, C., Bordi, F., and Carafa, M. (2021). Rifampicin-liposomes for Mycobacterium abscessus infection treatment: Intracellular uptake and antibacterial activity evaluation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071070"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e0254621","DOI":"10.1128\/spectrum.02546-21","article-title":"Combined host- and pathogen-directed therapy for the control of Mycobacterium abscessus infection","volume":"10","author":"Poerio","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Slavin, Y.N., Ivanova, K., Tang, W.L., Tzanov, T., Li, S.D., and Bach, H. (2021). Targeting intracellular mycobacteria using nanosized niosomes loaded with antibacterial agents. Nanomaterials, 11.","DOI":"10.3390\/nano11081984"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/14786419.2019.1598987","article-title":"Phytochemical analysis and evaluation of antioxidant and antimycobacterial activity of Colletia paradoxa from Brazil","volume":"35","author":"Piana","year":"2021","journal-title":"Nat. Prod. Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Jimenez-Arellanes, A., Luna-Herrera, J., Ruiz-Nicolas, R., Cornejo-Garrido, J., Tapia, A., and Yepez-Mulia, L. (2013). Antiprotozoal and antimycobacterial activities of Persea americana seeds. BMC Complement. Altern. Med., 13.","DOI":"10.1186\/1472-6882-13-109"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e12391","DOI":"10.7717\/peerj.12391","article-title":"Assessment of antimycobacterial activities of pure compounds extracted from Thai medicinal plants against clarithromycin-resistant Mycobacterium abscessus","volume":"9","author":"Sirichoat","year":"2021","journal-title":"PeerJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4635\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:44:14Z","timestamp":1760121854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24054635"],"URL":"https:\/\/doi.org\/10.3390\/ijms24054635","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}